Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.11%) | PASS |
| Cash Ratio (0.19%) | PASS |
| Receivables Ratio (0.23%) | PASS |
| Revenue Ratio (0.16%) | FAIL |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-31 | -2.09 | Pending | -- |
| 2026-04-30 | -3.88 | -3.40 | +12.4% |
| 2026-02-13 | -2.60 | -2.11 | +18.9% |
| 2025-11-06 | -2.16 | -0.51 | +76.4% |
| 2025-08-01 | -2.97 | -2.13 | +28.3% |
| 2025-05-01 | -3.11 | -2.52 | +18.9% |
| 2025-02-14 | -2.73 | -2.91 | -6.7% |
| 2024-11-07 | -1.94 | 0.03 | +101.5% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $389.0M | -$1.3B | -$1.3B | -$566.0M | -$1.4B | -3.40 |
| 2025-12-31 | $676.0M | -$826.0M | -$724.0M | $224.0M | -$857.0M | -2.11 |
| 2025-09-30 | $1.0B | -$200.0M | -$135.0M | $795.0M | -$260.0M | -0.51 |
| 2025-06-30 | $137.0M | -$825.0M | -$760.0M | $18.0M | -$907.0M | -2.13 |
| 2025-03-31 | $107.0M | -$971.0M | -$924.0M | $17.0M | -$1.1B | -2.52 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-15 | HOGE STEPHEN | President | 53,336 | $1.0M |
| 2026-05-15 | HOGE STEPHEN | President | 53,336 | $2.6M |
| 2026-05-01 | HUSSAIN SHAH ABBAS | Director | 5,682 | $265.0K |
| 2026-04-30 | HUSSAIN SHAH ABBAS | Director | 16,233 | -- |
| 2026-04-30 | NABEL ELIZABETH G | Director | 16,233 | -- |
| 2026-04-30 | HORNING SANDRA | Director | 16,233 | -- |
| 2026-04-30 | TALLETT ELIZABETH E | Director | 4,058 | -- |
| 2026-04-30 | NADER FRANCOIS E. | Director | 12,174 | -- |
| 2026-04-30 | RUBENSTEIN DAVID M | Director | 8,116 | -- |
| 2026-04-02 | MOCK JAMES M | Chief Financial Officer | 1,453 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| FMR, LLC | 45.7M | $2.1B | 0.1% |
| Blackrock Inc. | 29.6M | $1.4B | 0.1% |
| Vanguard Capital Management LLC | 22.9M | $1.1B | 0.1% |
| BAILLIE GIFFORD & CO | 20.0M | $936.9M | 0.1% |
| Capital World Investors | 18.7M | $876.5M | 0.0% |
| Vanguard Portfolio Management LLC | 15.6M | $732.1M | 0.0% |
| State Street Corporation | 14.9M | $696.7M | 0.0% |
| Geode Capital Management, LLC | 9.4M | $442.3M | 0.0% |
| Two Sigma Investments, LP | 9.1M | $426.0M | 0.0% |
| Morgan Stanley | 8.5M | $397.1M | 0.0% |
$14.7B
2.14
1.056
19
$2.2B
$1.3B
2.96
10.34
0.2%
4,700
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-31 | $-2.09 | Pending | — |
| 2026-04-30 | $-3.88 | $-3.40 | +12.4% |
| 2026-02-13 | $-2.60 | $-2.11 | +18.9% |
| 2025-11-06 | $-2.16 | $-0.51 | +76.4% |
| 2025-08-01 | $-2.97 | $-2.13 | +28.3% |
| 2025-05-01 | $-3.11 | $-2.52 | +18.9% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($43.20, 20 analysts) | |||
| 10 | $543.50 | +$-111.50 (-21%) | -1.4R |
| 50 | $2,717.50 | +$-557.50 (-21%) | -1.4R |
| 100 | $5,435.00 | +$-1,115.00 (-21%) | -1.4R |
- Elevated short interest (10.34 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ARKG | 0.507 |
| NVAX | 0.489 |
| HQH | 0.461 |
| CRSP | 0.438 |
| RXRX | 0.431 |
| Ticker | Correlation |
|---|---|
| MO | -0.172 |
| KR | -0.172 |
| BAES.L | -0.169 |
| COL.AX | -0.164 |
| AGL.AX | -0.140 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.